Genitourinary Cancers | Specialty

Exelixis Completes Rolling Submission for Cabozantinib in RCC

December 23rd 2015

A new drug application has been submitted for cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received one prior therapy.

Dr. Figlin on Advice for Oncologists Treating RCC

December 22nd 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, provides advice to community oncologists who are treating patients with renal cell carcinoma.

Lenvatinib in Metastatic Renal Cell Carcinoma

December 19th 2015

PD-1 Inhibition in Metastatic Renal Cell Carcinoma

December 19th 2015

Perspectives on Sequencing in Metastatic RCC

December 19th 2015

Goals in Relapsed/Refractory Metastatic RCC

December 19th 2015

mTOR Inhibition for Poor-Risk RCC

December 19th 2015

Frontline Therapy Selection in Metastatic RCC

December 19th 2015

Frontline TKI Selection in Metastatic RCC

December 19th 2015

First-Line Considerations in Metastatic Renal Cell Carcinoma

December 19th 2015

Advanced Prostate Cancer Clinics Make Inroads in Practices

December 15th 2015

Gary Kirsh, MD, president of The Urology Group and LUGPA, Kirsh provides insight on treating prostate cancer within the context of urology, as well as the benefits of a multidisciplinary approach.

Dr. Petrylak on Atezolizumab in Bladder Cancer

December 15th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

UC Davis Meets NCI-Designation With Great Responsibility

November 30th 2015

Conference Highlights, Three FDA Approvals, and More

November 30th 2015

Personalized Peptide Vaccination Increased Survival in Advanced Bladder Cancer

November 28th 2015

The prognosis for patients with bladder cancer who have progressed after platinum-based chemotherapy is poor, but the results of a phase II study involving an immunotherapy hold promise.

FDA Approves Nivolumab for Metastatic Renal Cell Carcinoma

November 23rd 2015

The FDA has approved nivolumab as a treatment for patients with metastatic renal cell carcinoma following prior treatment with an anti-angiogenic therapy.

Checkpoint Inhibitors Generate Renewed Excitement in RCC

November 18th 2015

With several novel therapies approaching regulatory approval, the treatment landscape for renal cell carcinoma is facing a major upheaval.

FDA Panel Rejects Immunotherapy MCNA in Bladder Cancer

November 18th 2015

An FDA panel voted against approval of the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guérin therapy.

FDA Grants Priority Review to Nivolumab for Renal Cell Carcinoma

November 16th 2015

The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab as a treatment for patients with advanced renal cell carcinoma following prior antiangiogenic therapy.

Promising Immunotherapy Agents on Horizon in Bladder Cancer

November 16th 2015

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.